Oncology – Page 6

Routine Whole‑Body Imaging Did Not Improve Early Survival in High‑Risk Melanoma: Interim TRIM Trial Analysis

By MedXY 11/05/2025

Interim results from the multicentre phase 3 TRIM trial show no survival benefit from adding scheduled whole‑body CT or FDG‑PET‑CT to physical‑examination follow‑up after radical surgery for stage IIB–C and III cutaneous melanoma at median 33.6 months.

Gastroenterology news Oncology

Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival

By MedXY 11/05/2025

Olverembatinib showed outstanding efficacy in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), significantly extending median progression-free survival to 25.7 months compared to traditional therapies.

AI news Oncology Pediatrics

AI-RAPNO: Translating Artificial Intelligence into Reliable Response Assessment for Pediatric Neuro-Oncology

By MedXY 11/04/2025

AI-RAPNO synthesizes current AI developments for pediatric brain tumour imaging and provides practical recommendations to improve trustworthiness, generalisability, and clinical implementation of AI-driven response assessment using the RAPNO framework.

Neurology news Oncology

Vorasidenib Slows Tumour Growth and Reduces Seizures in IDH‑Mutant Grade 2 Glioma — Robust PFS and Preserved Cognition in the INDIGO Phase 3 Trial

By MedXY 11/04/2025

In the INDIGO phase 3 trial, vorasidenib markedly prolonged progression‑free survival and time to next intervention, reduced volumetric tumour growth and seizure burden, and preserved quality of life and neurocognitive function in patients with grade 2 IDH1/2‑mutant diffuse glioma after surgery.

news Oncology Otorhinolaryngology

Lower, More Frequent Cisplatin Dosing Substantially Reduces Hearing Loss in Head and Neck Cancer Without Compromising Short‑Term Survival

By MedXY 11/04/2025

A multicenter retrospective cohort shows weekly low‑dose cisplatin markedly lowers ototoxicity compared with standard high‑dose every‑3‑week cisplatin in CRT for head and neck squamous cell carcinoma, with similar two‑year survival.

news Oncology

Ivonescimab (PD‑1/VEGF bispecific) Plus Chemo Outperforms PD‑1+Chemo in First‑Line Advanced Squamous NSCLC: HARMONi‑6 Results Redefine a Tough Indication

By MedXY 11/02/2025

Phase 3 HARMONi‑6: ivonescimab + paclitaxel/carboplatin increased median PFS to 11.1 vs 6.9 months (HR 0.60, P<0.0001) and improved ORR versus tislelizumab+chemo in first‑line advanced squamous NSCLC, with low major bleeding (≥ grade 3, 1.9%).

Allergy & Immunology Family Medicine & Nutrition news Oncology

How Milk Sugar Fuels Immune Cells to Fight Cancer: The Surprising Role of Galactose

By MedXY 11/01/2025

New research reveals that galactose from dietary sources like milk reprograms liver metabolism, boosting immune T cell activity to combat tumors by preventing their exhaustion.

news Oncology Public Health

Hair Straighteners, Chemical Relaxers, Increase Risk of Non‑Reproductive Cancers

By MedXY 11/01/2025

A US cohort study (Sister Study) found that recent use of hair straighteners/chemical relaxers was associated with higher incidence of thyroid cancer, pancreatic cancer, and a possible increase in non‑Hodgkin lymphoma; associations were imprecise and showed little dose–response.

Neurology news Oncology

Patritumab Deruxtecan (HER3-DXd) Shows Promising Activity in Breast Cancer Patients with Active Brain Metastases: Insights from the TUXEDO-3 Phase 2 Trial

By MedXY 10/31/2025

The TUXEDO-3 trial demonstrates that patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, offers clinical benefit and a manageable safety profile in metastatic breast cancer patients with active brain metastases.

news Oncology Urology

European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile

By MedXY 10/31/2025

The 23-year follow-up of the ERSPC confirms that PSA screening reduces prostate cancer mortality by 13%, with an improved harm-benefit ratio, supporting risk-based screening strategies to optimize outcomes.

news OB/GYN & Women's Health Oncology

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By MedXY 10/31/2025

Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.

news Oncology Urology

Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

A retrospective study in US veterans reveals increased use of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), showing improved survival over ADT alone. ARPIs and docetaxel demonstrate comparable overall survival, with ARPIs providing longer progression-free survival.

news Oncology Urology

Age-Dependent Benefits of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Meta-Analysis

By MedXY 10/30/2025

This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease volume.

news Oncology Radiology Urology

Visual Whole-Body Tumor-Burden Classification via PSMA PET/CT: Advancing Prognostic Stratification and Therapy Response Prediction in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

A novel PSMA PET/CT-based tumor-burden classification effectively stratifies metastatic hormone-sensitive prostate cancer patients, predicting response and prognosis with androgen receptor signaling inhibitors, especially second-generation treatments.

news Oncology Urology

Optimizing Therapy for Older Patients with Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Network Meta-Analysis of Doublet versus Triplet Regimens

By MedXY 10/30/2025

This network meta-analysis reveals that triplet therapy with darolutamide, ADT, and docetaxel offers the greatest overall survival benefit for older patients with metastatic hormone-sensitive prostate cancer, highlighting the need to balance efficacy and toxicity.

news Oncology Urology

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains from intensified therapy.

Gastroenterology news Oncology

Advances in Gastrointestinal Cancer Therapeutics: Insights from NICHE-2, FOxTROT, Telisotuzumab Adizutecan, and Emerging Trials

By MedXY 10/30/2025

This article reviews pivotal updates in gastrointestinal oncology from recent trials, emphasizing superior neoadjuvant immunotherapy in mismatch repair–deficient colorectal cancer, promising antibody-drug conjugates, and challenges in novel combination therapies.

news Oncology

Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma

By MedXY 10/30/2025

In the phase 3 CARES-009 trial, perioperative camrelizumab combined with rivoceranib significantly improved event-free survival and major pathological response in patients with resectable high-risk hepatocellular carcinoma, compared to surgery alone.

news Oncology

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma

By MedXY 10/30/2025

Phase 3 TALENTop trial interim results show liver resection following atezolizumab plus bevacizumab induction significantly prolongs time to treatment failure in advanced HCC without extrahepatic spread.

news Oncology Respiratory

Comparative Effectiveness and Safety of PD-L1 Inhibitors with Chemotherapy in Extensive-Stage Small Cell Lung Cancer: Insights from a French Nationwide Cohort Study

By MedXY 10/29/2025

A French nationwide cohort study reveals no significant differences in effectiveness or safety between atezolizumab and durvalumab as first-line PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer.